This Obesity Biotech Is Going Mobile
Mobile devices today have become ubiquitous, and tech companies are not the only ones trying to profit from this trend. Drugmakers have also started to catch on to the power of marketing through smartphones. Sanofi , a leading provider of long-acting diabetes medications, was one of the first movers in this space and has a blood glucose monitor that works with iPhones.
Today, obesity drugmaker VIVUS announced that it is also getting in on this emerging trend. In an effort to further entice patients to try its obesity medication, Qsymia, VIVUS has announced a new mobile app that can help patients comply with their treatment. Health care analyst Max Macaluso discusses this story -- and what it means for investors -- in the following video.
Who will win the obesity drug market?
Can VIVUS pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.
The article This Obesity Biotech Is Going Mobile originally appeared on Fool.com.Max Macaluso, Ph.D. owns shares of Apple. The Motley Fool recommends Apple. The Motley Fool owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.